Artigos de revistas sobre o tema "Abstract Targeted radionuclide therapy (TRT)"
Crie uma referência precisa em APA, MLA, Chicago, Harvard, e outros estilos
Veja os 50 melhores artigos de revistas para estudos sobre o assunto "Abstract Targeted radionuclide therapy (TRT)".
Ao lado de cada fonte na lista de referências, há um botão "Adicionar à bibliografia". Clique e geraremos automaticamente a citação bibliográfica do trabalho escolhido no estilo de citação de que você precisa: APA, MLA, Harvard, Chicago, Vancouver, etc.
Você também pode baixar o texto completo da publicação científica em formato .pdf e ler o resumo do trabalho online se estiver presente nos metadados.
Veja os artigos de revistas das mais diversas áreas científicas e compile uma bibliografia correta.
Nguyen, Thanh Phuong T., Caroline P. Kerr, Joseph J. Grudzinski, Carolina A. Ferreira, Julia Sheehan-Klenk, Ohyun Kwon, Maria Powers et al. "Abstract 6407: Radionuclide-specific effects of90Y-,177Lu-, or225Ac-NM600 targeted radionuclide therapy on tumor immunomodulation and enhanced immunotherapy response in syngeneic murine tumors". Cancer Research 83, n.º 7_Supplement (4 de abril de 2023): 6407. http://dx.doi.org/10.1158/1538-7445.am2023-6407.
Texto completo da fonteKerr, Caroline P., Joseph J. Grudzinski, Carolina A. Ferreira, David Adam, Julia Sheehan-Klenk, Amber M. Bates, Won Jong Jin et al. "Abstract 2828: Impact of sequencing of immune checkpoint blockade and targeted radionuclide therapy on murine tumor response". Cancer Research 83, n.º 7_Supplement (4 de abril de 2023): 2828. http://dx.doi.org/10.1158/1538-7445.am2023-2828.
Texto completo da fontePal, Debjani, Miguel Toro Gonzáleza, Amber N. Bibleb, Brian Sanders, Anna Plechaty, Owee Kirpekar, Mircea Podar e Sandra M. Davern. "Abstract 480: Nanotherapeutic strategies to improve targeted radionuclide therapy". Cancer Research 84, n.º 6_Supplement (22 de março de 2024): 480. http://dx.doi.org/10.1158/1538-7445.am2024-480.
Texto completo da fonteAdhikarla, Vikram, Dennis Awuah, Alexander B. Brummer, Enrico Caserta, Amrita Krishnan, Flavia Pichiorri, Megan M. Minnix et al. "Abstract 2732: A mathematical model for optimization of combination therapy involving targeted radionuclide and CAR-T cell therapy". Cancer Research 82, n.º 12_Supplement (15 de junho de 2022): 2732. http://dx.doi.org/10.1158/1538-7445.am2022-2732.
Texto completo da fonteKerr, Caroline P., Amber M. Bates, Joseph J. Grudzinski, Carolina A. Ferreira, Julia Sheehan-Klenk, David Adam, Maria Powers et al. "Abstract 1306: Radionuclide-specific effects of 90Y-, 177Lu-, or 225Ac-NM600 targeted radionuclide therapy on tumor immunomodulation and enhancing immunotherapy response in murine tumor models". Cancer Research 82, n.º 12_Supplement (15 de junho de 2022): 1306. http://dx.doi.org/10.1158/1538-7445.am2022-1306.
Texto completo da fonteAdhikarla, Vikram, Dennis Awuah, Enrico Caserta, Megan Minnix, Maxim Kuznetsov, Amrita Krishnan, Jeffrey Y. Wong et al. "Abstract 7374: Mathematical modeling of targeted radionuclide therapy and CAR-T cell immunotherapy for maximizing therapeutic efficacy in multiple myeloma". Cancer Research 84, n.º 6_Supplement (22 de março de 2024): 7374. http://dx.doi.org/10.1158/1538-7445.am2024-7374.
Texto completo da fonteRuder, Samuel, Michael Sun, Andres Ricaurte Fajardo, Jones Nauseef, Zachary Davidson, Joseph Thomas, Sandra Huicochea Castellanos et al. "Abstract 7582: Descriptive analysis of patients with mCRPC and liver metastases receiving alpha and beta PSMA targeted radionuclide therapy (PSMA-TRT)". Cancer Research 84, n.º 6_Supplement (22 de março de 2024): 7582. http://dx.doi.org/10.1158/1538-7445.am2024-7582.
Texto completo da fonteSheehan-Klenk, Julia, Caroline P. Kerr, Thanh P. Nguyen, Joseph J. Grudzinski, David Adam, Maria Powers, Raghava N. Sriramaneni et al. "Abstract 6117: Dose, dose rate, and linear energy transfer influence tumor immunologic and DNA damage response following alpha- and beta-emitting radionuclides". Cancer Research 83, n.º 7_Supplement (4 de abril de 2023): 6117. http://dx.doi.org/10.1158/1538-7445.am2023-6117.
Texto completo da fonteVorontsova, M., T. Karmakova, A. Pankratov e A. Kaprin. "Current Trends in Targeted Radionuclide Therapy Development". Medical Radiology and radiation safety 66, n.º 6 (17 de dezembro de 2021): 63–70. http://dx.doi.org/10.12737/1024-6177-2021-66-6-63-70.
Texto completo da fontevan der Wal, Bart C. H., e Ekaterina Dadachova. "Targeted Radionuclide Therapy of Cancer and Infections". International Journal of Molecular Sciences 24, n.º 10 (22 de maio de 2023): 9081. http://dx.doi.org/10.3390/ijms24109081.
Texto completo da fonteMetcalf, Julie, Alexander Nielsen, Suma Prabhu, Nicole Robinson, Sarah Marinacci, Natalie Grinshtein, Brigitte L. Theriault et al. "Abstract LB313: EGFRvIII-targeted alpha therapy shows significant therapeutic efficacy as both a single-agent and in combination with standard of care against preclinical GBM models". Cancer Research 83, n.º 8_Supplement (14 de abril de 2023): LB313. http://dx.doi.org/10.1158/1538-7445.am2023-lb313.
Texto completo da fonteKerr, Caroline P., Joseph J. Grudzinski, Thanh Phuong Nguyen, Reinier Hernandez, Jamey P. Weichert e Zachary S. Morris. "Developments in Combining Targeted Radionuclide Therapies and Immunotherapies for Cancer Treatment". Pharmaceutics 15, n.º 1 (30 de dezembro de 2022): 128. http://dx.doi.org/10.3390/pharmaceutics15010128.
Texto completo da fonteObata, Honoka, Mikako Ogawa e Michael R. Zalutsky. "DNA Repair Inhibitors: Potential Targets and Partners for Targeted Radionuclide Therapy". Pharmaceutics 15, n.º 7 (11 de julho de 2023): 1926. http://dx.doi.org/10.3390/pharmaceutics15071926.
Texto completo da fonteLi, Mengshi, Edwin A. Sagastume, Dongyoul Lee, Daniel McAlister, Anthony J. DeGraffenreid, Keith R. Olewine, Stephen Graves et al. "203/212Pb Theranostic Radiopharmaceuticals for Image-guided Radionuclide Therapy for Cancer". Current Medicinal Chemistry 27, n.º 41 (8 de dezembro de 2020): 7003–31. http://dx.doi.org/10.2174/0929867327999200727190423.
Texto completo da fonteAdhikarla, Vikram, Dennis Awuah, Alexander B. Brummer, Enrico Caserta, Amrita Krishnan, Flavia Pichiorri, Megan Minnix et al. "A Mathematical Modeling Approach for Targeted Radionuclide and Chimeric Antigen Receptor T Cell Combination Therapy". Cancers 13, n.º 20 (15 de outubro de 2021): 5171. http://dx.doi.org/10.3390/cancers13205171.
Texto completo da fonteMalcolm, Javian, Nadia Falzone, Boon Lee e Katherine Vallis. "Targeted Radionuclide Therapy: New Advances for Improvement of Patient Management and Response". Cancers 11, n.º 2 (25 de fevereiro de 2019): 268. http://dx.doi.org/10.3390/cancers11020268.
Texto completo da fonteRuigrok, Eline A. M., Wytske M. van Weerden, Julie Nonnekens e Marion de Jong. "The Future of PSMA-Targeted Radionuclide Therapy: An Overview of Recent Preclinical Research". Pharmaceutics 11, n.º 11 (29 de outubro de 2019): 560. http://dx.doi.org/10.3390/pharmaceutics11110560.
Texto completo da fonteMüller, Cristina, Martin Béhé, Susanne Geistlich, Nicholas P. van der Meulen e Roger Schibli. "Targeted Radiotherapeutics from 'Bench-to-Bedside'". CHIMIA International Journal for Chemistry 74, n.º 12 (23 de dezembro de 2020): 939–45. http://dx.doi.org/10.2533/chimia.2020.939.
Texto completo da fontePatel, Ravi B., Reinier Hernandez, Peter Carlson, Joseph Grudzinski, Amber M. Bates, Justin C. Jagodinsky, Amy Erbe et al. "Low-dose targeted radionuclide therapy renders immunologically cold tumors responsive to immune checkpoint blockade". Science Translational Medicine 13, n.º 602 (14 de julho de 2021): eabb3631. http://dx.doi.org/10.1126/scitranslmed.abb3631.
Texto completo da fonteSun, M., C. Thomas, J. Stangl-Kremser, A. Fajardo, J. Palmer, J. Thomas, S. Huicochea Castellanos et al. "1822P PSMA-alpha targeted radionuclide therapy (TRT) with or without prior PSMA-beta TRT". Annals of Oncology 34 (outubro de 2023): S987. http://dx.doi.org/10.1016/j.annonc.2023.09.2770.
Texto completo da fonteSpoormans, Kaat, Melissa Crabbé, Lara Struelens, Marijke De Saint-Hubert e Michel Koole. "A Review on Tumor Control Probability (TCP) and Preclinical Dosimetry in Targeted Radionuclide Therapy (TRT)". Pharmaceutics 14, n.º 10 (22 de setembro de 2022): 2007. http://dx.doi.org/10.3390/pharmaceutics14102007.
Texto completo da fonteAprile, Carlo, Onelio Geatti, Letizia Canziani e Lorenzo Lodola. "Editorial for the Special Issue “Molecular Biology in Targeted Radionuclide Therapy Radiopharmaceutical Design”". Current Issues in Molecular Biology 46, n.º 3 (13 de março de 2024): 2398–401. http://dx.doi.org/10.3390/cimb46030152.
Texto completo da fonteFuneh, Cyprine Neba, Jessica Bridoux, Thomas Ertveldt, Timo W. M. De Groof, Dora Mugoli Chigoho, Parinaz Asiabi, Peter Covens, Matthias D’Huyvetter e Nick Devoogdt. "Optimizing the Safety and Efficacy of Bio-Radiopharmaceuticals for Cancer Therapy". Pharmaceutics 15, n.º 5 (30 de abril de 2023): 1378. http://dx.doi.org/10.3390/pharmaceutics15051378.
Texto completo da fontePotluri, Hemanth, Carolina Ferreira, Joseph Grudzinski, Christopher Massey, Reinier Hernandez, Jamey Weichert e Douglas McNeel. "594 Combination of antigen-specific vaccination and targeted radionuclide therapy improves anti-tumor efficacy in a murine prostate model". Journal for ImmunoTherapy of Cancer 9, Suppl 2 (novembro de 2021): A624. http://dx.doi.org/10.1136/jitc-2021-sitc2021.594.
Texto completo da fonteDelpassand, Ebrahim S., Mohammad Jawed Hashmi, Julia Kazakin, Omer Nawaz, Gabriella Garufi, Joanne Schindler e Luke Nordquist. "Abstract CT224: Preliminary efficacy and safety results from the (TATCIST) trial: A PSMA-directed targeted alpha therapy with FPI-2265 (225Ac-PSMA-I&T) for the treatment of metastatic castration-resistant prostate cancer (mCRPC)". Cancer Research 84, n.º 7_Supplement (5 de abril de 2024): CT224. http://dx.doi.org/10.1158/1538-7445.am2024-ct224.
Texto completo da fonteRuigrok, Eline A. M., Nicole S. Verkaik, Erik de Blois, Corrina de Ridder, Debra Stuurman, Stefan J. Roobol, Dik C. Van Gent, Marion de Jong, Wytske M. Van Weerden e Julie Nonnekens. "Preclinical Assessment of the Combination of PSMA-Targeting Radionuclide Therapy with PARP Inhibitors for Prostate Cancer Treatment". International Journal of Molecular Sciences 23, n.º 14 (21 de julho de 2022): 8037. http://dx.doi.org/10.3390/ijms23148037.
Texto completo da fonteWilliams, L. "WE-E-214-03: Biology and Physiology of Targeted Radionuclide Therapy (TRT)". Medical Physics 38, n.º 6Part33 (junho de 2011): 3822. http://dx.doi.org/10.1118/1.3613392.
Texto completo da fonteSpeer, T. W., P. Bernhardt, B. Bednarz, P. Harari, J. Saker e B. Thomadsen. "Feasibility of the Systemic Cure of Cancer With Targeted Radionuclide Therapy (TRT)". International Journal of Radiation Oncology*Biology*Physics 84, n.º 3 (novembro de 2012): S709. http://dx.doi.org/10.1016/j.ijrobp.2012.07.1898.
Texto completo da fontePotluri, Hemanth K., Carolina A. Ferreira, Joseph Grudzinski, Christopher Massey, Eduardo Aluicio-Sarduy, Jonathan W. Engle, Ohyun Kwon et al. "Antitumor efficacy of 90Y-NM600 targeted radionuclide therapy and PD-1 blockade is limited by regulatory T cells in murine prostate tumors". Journal for ImmunoTherapy of Cancer 10, n.º 8 (agosto de 2022): e005060. http://dx.doi.org/10.1136/jitc-2022-005060.
Texto completo da fonteAkil, Hussein, Mercedes Quintana, Jérémy H. Raymond, Tommy Billoux, Valentin Benboubker, Sophie Besse, Philippe Auzeloux et al. "Efficacy of Targeted Radionuclide Therapy Using [131I]ICF01012 in 3D Pigmented BRAF- and NRAS-Mutant Melanoma Models and In Vivo NRAS-Mutant Melanoma". Cancers 13, n.º 6 (20 de março de 2021): 1421. http://dx.doi.org/10.3390/cancers13061421.
Texto completo da fonteMüller, Cristina, Maria De Prado Leal, Marco D. Dominietto, Christoph A. Umbricht, Sairos Safai, Rosalind L. Perrin, Martina Egloff et al. "Combination of Proton Therapy and Radionuclide Therapy in Mice: Preclinical Pilot Study at the Paul Scherrer Institute". Pharmaceutics 11, n.º 9 (2 de setembro de 2019): 450. http://dx.doi.org/10.3390/pharmaceutics11090450.
Texto completo da fonteMdanda, Sipho, Lindokuhle M. Ngema, Amanda Mdlophane, Mike M. Sathekge e Jan Rijn Zeevaart. "Recent Innovations and Nano-Delivery of Actinium-225: A Narrative Review". Pharmaceutics 15, n.º 6 (13 de junho de 2023): 1719. http://dx.doi.org/10.3390/pharmaceutics15061719.
Texto completo da fonteSun, M., C. Thomas, F. Orlando, M. Sigouros, J. Osborne, J. Nauseef, A. M. Molina et al. "1390P Circulating tumor DNA (ctDNA) and prognosis with PSMA-targeted radionuclide therapy (TRT)". Annals of Oncology 33 (setembro de 2022): S1179. http://dx.doi.org/10.1016/j.annonc.2022.07.1522.
Texto completo da fontede Roode, Kim E., Lieke Joosten e Martin Behe. "Towards the Magic Radioactive Bullet: Improving Targeted Radionuclide Therapy by Reducing the Renal Retention of Radioligands". Pharmaceuticals 17, n.º 2 (16 de fevereiro de 2024): 256. http://dx.doi.org/10.3390/ph17020256.
Texto completo da fonteCortiana, Viviana, Jade Gambill, Harshal Chorya, Diksha Mahendru, Fabiha Amin, Chandler H. Park e Yan Leyfman. "PSMA-Targeted Therapy: Advancements in Detection and Treatment Modalities with Dr. Scott T. Tagawa". Cancers 16, n.º 10 (11 de maio de 2024): 1833. http://dx.doi.org/10.3390/cancers16101833.
Texto completo da fonteSun, Michael, Charlene Thomas, Benedict Ho, Muhammad Junaid Niaz, Ana M. Molina, Cora N. Sternberg, David M. Nanus, Neil Harrison Bander e Scott T. Tagawa. "Long-term adverse events (AE) in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving prostate-specific membrane antigen (PSMA)-based targeted radionuclide therapy (TRT)." Journal of Clinical Oncology 39, n.º 15_suppl (20 de maio de 2021): 5055. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.5055.
Texto completo da fonteThomas, Joseph Earl, Jones T. Nauseef, Michael Philip Sun, Amie Patel, Angela Tan, Mahelia Bissassar, Jyothi Manohar et al. "Increased utilization of prostate-specific membrane antigen (PSMA)-targeted radionuclide therapy (PSMA-TRT) in African American (AA) patients at an academic medical center." Journal of Clinical Oncology 41, n.º 6_suppl (20 de fevereiro de 2023): 36. http://dx.doi.org/10.1200/jco.2023.41.6_suppl.36.
Texto completo da fonteSodji, Quaovi H., Matthew H. Forsberg, Dan Cappabianca, Caroline P. Kerr, Lauren Sarko, Amanda Shea, David P. Adam et al. "Comparative Study of the Effect of Radiation Delivered by Lutetium-177 or Actinium-225 on Anti-GD2 Chimeric Antigen Receptor T Cell Viability and Functions". Cancers 16, n.º 1 (30 de dezembro de 2023): 191. http://dx.doi.org/10.3390/cancers16010191.
Texto completo da fonteLi, Mengshi, Dijie Liu, Dongyoul Lee, Yinwen Cheng, Nicholas J. Baumhover, Brenna M. Marks, Edwin A. Sagastume et al. "Targeted Alpha-Particle Radiotherapy and Immune Checkpoint Inhibitors Induces Cooperative Inhibition on Tumor Growth of Malignant Melanoma". Cancers 13, n.º 15 (22 de julho de 2021): 3676. http://dx.doi.org/10.3390/cancers13153676.
Texto completo da fonteEverix, Liesbeth, Shankari Nair, Cathryn H. S. Driver, Ingeborg Goethals, Mike M. Sathekge, Thomas Ebenhan, Charlot Vandevoorde e Julie Bolcaen. "Perspective on the Use of DNA Repair Inhibitors as a Tool for Imaging and Radionuclide Therapy of Glioblastoma". Cancers 14, n.º 7 (3 de abril de 2022): 1821. http://dx.doi.org/10.3390/cancers14071821.
Texto completo da fonteMagee, Kara, Ian R. Marsh, Michelle M. Turek, Joseph Grudzinski, Eduardo Aluicio-Sarduy, Jonathan W. Engle, Ilene D. Kurzman et al. "Safety and feasibility of an in situ vaccination and immunomodulatory targeted radionuclide combination immuno-radiotherapy approach in a comparative (companion dog) setting". PLOS ONE 16, n.º 8 (12 de agosto de 2021): e0255798. http://dx.doi.org/10.1371/journal.pone.0255798.
Texto completo da fonteMuralidhar, Anusha, Reinier Hernandez, Zachary S. Morris, Hansel Comas Rojas, Malick Bio Idrissou, Jamey P. Weichert e Douglas G. McNeel. "Myeloid-derived suppressor cells attenuate the antitumor efficacy of radiopharmaceutical therapy using90Y-NM600 in combination with androgen deprivation therapy in murine prostate tumors". Journal for ImmunoTherapy of Cancer 12, n.º 4 (abril de 2024): e008760. http://dx.doi.org/10.1136/jitc-2023-008760.
Texto completo da fonteMétivier, Cassandra, Patricia Le Saëc, Joëlle Gaschet, Catherine Chauvet, Séverine Marionneau-Lambot, Peter O. Hofgaard, Bjarne Bogen et al. "Preclinical Evaluation of a 64Cu-Based Theranostic Approach in a Murine Model of Multiple Myeloma". Pharmaceutics 15, n.º 7 (25 de junho de 2023): 1817. http://dx.doi.org/10.3390/pharmaceutics15071817.
Texto completo da fonteVlachostergios, Panagiotis J., Muhammad Junaid Niaz, Seyed Ali Mosallaie, Paul J. Christos, Amy Hackett, Joseph R. Osborne, Yuliya Jhanwar et al. "Association of noninvasive, radiographic measurement of prostate-specific membrane antigen (PSMA) expression with response to PSMA-targeted radionuclide therapy (TRT)." Journal of Clinical Oncology 37, n.º 15_suppl (20 de maio de 2019): 5013. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.5013.
Texto completo da fonteReiner, Dora, Matthias Blaickner e Frank Rattay. "Discrete beta dose kernel matrices for nuclides applied in targeted radionuclide therapy (TRT) calculated withMCNP5". Medical Physics 36, n.º 11 (2 de outubro de 2009): 4890–96. http://dx.doi.org/10.1118/1.3231995.
Texto completo da fonteSun, Michael, Justin M. Lebenthal, Jones T. Nauseef, Muhammad Junaid Niaz, Sabrina Guervil, Escarleth Fernandez, Amie Patel et al. "Baseline and post-treatment circulating tumor cell (CTC) counts with prostate-specific membrane antigen (PSMA)-targeted radionuclide therapy (TRT) in men with metastatic castration-resistant prostate cancer (mCRPC)." Journal of Clinical Oncology 39, n.º 6_suppl (20 de fevereiro de 2021): 158. http://dx.doi.org/10.1200/jco.2021.39.6_suppl.158.
Texto completo da fonteFernandes, Célia, Elisa Palma, Francisco Silva, Ana Belchior, Catarina I. G. Pinto, Joana F. Guerreiro, Hugo M. Botelho, Filipa Mendes, Paula Raposinho e António Paulo. "Searching for a Paradigm Shift in Auger-Electron Cancer Therapy with Tumor-Specific Radiopeptides Targeting the Mitochondria and/or the Cell Nucleus". International Journal of Molecular Sciences 23, n.º 13 (29 de junho de 2022): 7238. http://dx.doi.org/10.3390/ijms23137238.
Texto completo da fonteRao, Yi, Tara Viray, Kurt Gehlsen, Matt Harris, Lachlan McInnes, Olufolake Majekodunmi e Jason Lewis. "Abstract 6038: Copper-67 based targeted radiotherapy primes immunologically cold PDAC for immunotherapy". Cancer Research 84, n.º 6_Supplement (22 de março de 2024): 6038. http://dx.doi.org/10.1158/1538-7445.am2024-6038.
Texto completo da fonteRuder, Samuel Francis, Michael Philip Sun, Charlene Thomas, Ana M. Molina, Jones T. Nauseef, Joseph Osborne, Cora N. Sternberg, David M. Nanus, Neil Harrison Bander e Scott T. Tagawa. "Comparison of adverse event rate of prostate-specific membrane antigen (PSMA)-targeted radionuclide therapy (TRT) with antibody or small molecule ligand targeting vector." Journal of Clinical Oncology 42, n.º 4_suppl (1 de fevereiro de 2024): 161. http://dx.doi.org/10.1200/jco.2024.42.4_suppl.161.
Texto completo da fonteSanchez-Garcia, Manuel, Isabelle Gardin, Rachida Lebtahi e Arnaud Dieudonné. "A new approach for dose calculation in targeted radionuclide therapy (TRT) based on collapsed cone superposition: validation with90Y". Physics in Medicine and Biology 59, n.º 17 (6 de agosto de 2014): 4769–84. http://dx.doi.org/10.1088/0031-9155/59/17/4769.
Texto completo da fonte